Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HDR003
MIFTS: 48

Hidradenitis

Categories: Endocrine diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hidradenitis

About this section

MalaCards integrated aliases for Hidradenitis:

Name: Hidradenitis 12 44 15 72
Hydradenitis 12

Classifications:

MalaCards categories:
Anatomical: Skin diseases Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2282
ICD9CM 35 705.83
MeSH 44 D016575
NCIt 50 C112190
SNOMED-CT 68 69741000
UMLS 72 C0085160
Sources

Summaries for Hidradenitis

About this section
Disease Ontology : 12 A sweat gland disease that is characterized by inflammation of the apocrine sweat glands and has symptom erythema, edema, papules, plaques, pruritis, and pain.

MalaCards based summary : Hidradenitis, also known as hydradenitis, is related to pyoderma and pyoderma gangrenosum, and has symptoms including erythema An important gene associated with Hidradenitis is NCSTN (Nicastrin), and among its related pathways/superpathways are Developmental Biology and Th17 cell differentiation. The drugs Adalimumab and Anti-Inflammatory Agents have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, skin and breast, and related phenotypes are hematopoietic system and immune system

Wikipedia : 75 Hidradenitis is any disease in which the histologic abnormality is primarily an inflammatory infiltrate... more...

Sources

Related Diseases for Hidradenitis

About this section

Diseases related to Hidradenitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 375)
# Related Disease Score Top Affiliating Genes
1 pyoderma 31.4 TNF NOD2
2 pyoderma gangrenosum 31.4 TNF NOD2
3 crohn's colitis 31.3 TNF NOD2
4 inflammatory bowel disease 31.0 TNF NOD2 IL17A
5 spondylarthropathy 30.7 TNF NOD2
6 ulcerative colitis 30.7 TNF NOD2 IL17A
7 spondyloarthropathy 1 30.4 TNF NOD2 IL17A
8 spondylitis 30.4 TNF NOD2 IL17A
9 dermatitis, atopic 30.3 TNF IL17A CAMP
10 colitis 30.3 TNF NOD2 IL17A
11 rosacea 30.2 TNF CAMP
12 sweat gland disease 30.2 NCSTN KRT14
13 uveitis 30.1 TNF NOD2 IL17A
14 skin disease 30.1 TNF KRT14 KRT10 IL17A CAMP
15 psoriatic arthritis 30.1 TNF NOD2 IL17A
16 melkersson-rosenthal syndrome 29.9 TNF NOD2
17 dowling-degos disease 29.8 PSENEN NCSTN KRT14 DSC2
18 sarcoidosis 1 29.7 TNF NOD2 IL12RB1
19 bacterial infectious disease 29.7 TNF NOD2 IL17A CAMP
20 hidradenitis suppurativa 29.6 TNF PSENEN PSEN1 NOD2 NCSTN KRT14
21 lymphadenitis 29.5 TNF NOD2 IL12RB1
22 mycobacterium tuberculosis 1 29.5 TNF IL17A IL12RB1
23 pyoderma gangrenosum-acne-suppurative hidradenitis syndrome 12.4
24 acne inversa, familial, 1 11.8
25 perifolliculitis capitis abscedens et suffodiens, familial 11.6
26 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 11.5
27 acne inversa, familial, 2, with or without dowling-degos disease 11.5
28 papillon-lefevre syndrome 11.2
29 acne inversa, familial, 3 11.2
30 neurofibromatosis, type ii 10.9
31 crohn's disease 10.6
32 squamous cell carcinoma 10.6
33 sebaceous gland disease 10.6 PSENEN NCSTN
34 pustulosis of palm and sole 10.6
35 psoriasis 10.6
36 miller fisher syndrome 10.5 TNF PSENEN
37 ocular toxoplasmosis 10.5 NOD2 IL17A
38 granulomatous dermatitis 10.5 TNF NOD2
39 ileocolitis 10.5 TNF NOD2
40 trichosporonosis 10.5 TNF IL17A
41 streptococcal meningitis 10.5 TNF NOD2
42 inflammatory bowel disease 3 10.4 TNF NOD2
43 central nervous system vasculitis 10.4 TNF IL17A
44 folliculitis 10.4
45 orofacial granulomatosis 10.4 TNF NOD2
46 transverse myelitis 10.4 TNF IL17A
47 myelitis 10.4 TNF IL17A
48 autoimmune disease of eyes, ear, nose and throat 10.4 TNF IL17A
49 dysgraphia 10.4 PSEN1 CAMP
50 anal canal squamous cell carcinoma 10.4 PSENEN PSEN1 NCSTN

Graphical network of the top 20 diseases related to Hidradenitis:



Diseases related to Hidradenitis
Sources

Symptoms & Phenotypes for Hidradenitis

About this section

Symptoms:

12
  • • erythema

MGI Mouse Phenotypes related to Hidradenitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.86 CAMP IL12RB1 IL17A KRT14 NCSTN NOD2
2 immune system MP:0005387 9.76 CAMP IL12RB1 IL17A KRT14 NCSTN NOD2
3 craniofacial MP:0005382 9.72 IL17A KRT14 NCSTN PSEN1 TNF
4 mortality/aging MP:0010768 9.61 CAMP DSG2 IL17A KRT14 NCSTN NOD2
5 vision/eye MP:0005391 9.1 CAMP DSC2 KRT14 NCSTN PSEN1 TNF
Sources

Drugs & Therapeutics for Hidradenitis

About this section

Drugs for Hidradenitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved Phase 4 331731-18-1 16219006
2 Anti-Inflammatory Agents Phase 4
3 Anesthetics Phase 4
4 Anti-Bacterial Agents Phase 3
5 Antibiotics, Antitubercular Phase 3
6
Etanercept Approved, Investigational Phase 2 185243-69-0
7
Infliximab Approved Phase 2 170277-31-3
8
Ustekinumab Approved, Investigational Phase 2 815610-63-0
9
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
10
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
11 Brodalumab Approved, Investigational Phase 2 1174395-19-7
12
Ethinyl Estradiol Approved Phase 2 57-63-6 5991
13
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
14
Polyestradiol phosphate Approved Phase 2 28014-46-2
15
Drospirenone Approved Phase 2 67392-87-4 68873
16
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
17
Proline Approved, Nutraceutical Phase 2 147-85-3 145742
18 Analgesics Phase 2
19 Analgesics, Non-Narcotic Phase 2
20 Gastrointestinal Agents Phase 2
21 Peripheral Nervous System Agents Phase 2
22 Anti-Inflammatory Agents, Non-Steroidal Phase 2
23 Immunosuppressive Agents Phase 2
24 Interleukin 1 Receptor Antagonist Protein Phase 2
25 Angiogenesis Inhibitors Phase 2
26 Angiogenesis Modulating Agents Phase 2
27 lysine Phase 2
28 Antirheumatic Agents Phase 1, Phase 2
29 Complement System Proteins Phase 2
30 Complement C5a Phase 2
31 Anti-Infective Agents Phase 1, Phase 2
32 Antiparasitic Agents Phase 1, Phase 2
33 Antiprotozoal Agents Phase 1, Phase 2
34 Antimalarials Phase 1, Phase 2
35 Antibodies Phase 2
36 Immunologic Factors Phase 2
37 Antibodies, Monoclonal Phase 2
38 Immunoglobulins Phase 2
39 Dermatologic Agents Phase 2
40 Pharmaceutical Solutions Phase 2
41 Olive Phase 2
42 chlorophyllin Phase 2
43 Epidiolex Phase 2
44 Hormones Phase 2
45 Hormone Antagonists Phase 2
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
47 Contraceptives, Oral Phase 2
48 Estrogens Phase 2
49 Diuretics, Potassium Sparing Phase 2
50 diuretics Phase 2

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 Cost-effectiveness of Adalimumab With Adjuvant Surgery Versus Adalimumab Monotherapy in the Treatment of Hidradenitis Suppurativa' Recruiting NCT03221621 Phase 4 Adalimumab Injection
2 A Phase 4, Double-blind, Randomised, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT02808975 Phase 4 Adalimumab;Placebo
3 A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension) Completed NCT01635764 Phase 3
4 A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT02904902 Phase 3 adalimumab
5 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II Completed NCT01468233 Phase 3
6 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER I Completed NCT01468207 Phase 3
7 A Single Center Clinical Trial to Evaluate the Effect of Sclerotherapy on Fistulas and Sinus Tracts in Adult Patients With Hidradenitis Suppurativa Recruiting NCT02805595 Phase 3 23.4% Hypertonic saline;Saline
8 A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE) Recruiting NCT03713632 Phase 3 Secukinumab
9 A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE). Recruiting NCT03713619 Phase 3 secukinumab
10 To Determine The Efficacy Of A 1320nm Nd: YAG Nonablative Laser For Treatment of Hidradenitis Suppurativa Terminated NCT00367328 Phase 3
11 A Phase 2 Study of the Safety and Efficacy of Etanercept for the Therapy of Hydradenitis Suppurativa Completed NCT00329823 Phase 2 Etanercept sc 50mg per week for 12 weeks
12 A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Completed NCT03569371 Phase 2 INCB054707
13 A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03248531 Phase 2 Bimekizumab;Adalimumab
14 A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients Completed NCT02421172 Phase 2 Placebo
15 Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa Completed NCT00795574 Phase 2 infliximab;Placebo Comparator
16 Open Label,Phase Two Study to Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT00827996 Phase 2 adalimumab
17 An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03001622 Phase 2
18 A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica) Completed NCT01704534 Phase 2 Ustekinumab
19 An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa Completed NCT01516749 Phase 2 anakinra
20 A Phase II Open Label Clinical Trial of Etanercept for the Treatment of Hidradenitis Suppurativa Completed NCT00107991 Phase 2 etanercept
21 Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis: A Randomised Double-blind Placebo Controlled Trial Completed NCT03049267 Phase 2 Apremilast;Placebo Oral Tablet
22 A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa Completed NCT00918255 Phase 2 Placebo
23 A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa Completed NCT02695212 Phase 2 Apremilast
24 A Double-blind, Randomized, Placebo-controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa Completed NCT01558375 Phase 2 Water for injection;Anakinra
25 A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy Completed NCT02643654 Phase 2 MABp1;Placebo
26 A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Recruiting NCT03607487 Phase 2 INCB054707;Placebo
27 A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03827798 Phase 2 CFZ533;Placebo to CFZ533;LYS006;Placebo to LYS006
28 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03926169 Phase 2 Risankizumab;Placebo for risankizumab
29 A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03512275 Phase 2 Bermekimab Monoclonal Antibody 400 mg
30 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03852472 Phase 2 Avacopan
31 Clinical Efficacy of Inhibition of Organ Dysfunction Through Bermekimab in Systemic Sclerosis: A Proof- Of-Concept Double-Blind Randomized Clinical Trial (the Light Trial) Recruiting NCT04045743 Phase 2 MABp1 (Bermekimab) OR Placebo;MABp1 (Bermekimab)
32 A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT03487276 Phase 2 IFX-1;Placebo
33 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT03628924 Phase 2 Guselkumab dose 1;Guselkumab dose 2;Guselkumab dose 3;Placebo
34 Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Active, not recruiting NCT03275870 Phase 1, Phase 2 Hydroxychloroquine
35 Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. The HiGUS-trial Not yet recruiting NCT04061395 Phase 2
36 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Not yet recruiting NCT04019041 Phase 2 bermekimab;placebo
37 A Phase â…¡, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Not yet recruiting NCT03929835 Phase 2 Cannabis oil;Placebo
38 An Open-label Single Center Study to Evaluate the Efficacy of SILIQâ„¢ (Brodalumab) for the Treatment of Moderate Hidradenitis Suppurativa Not yet recruiting NCT03910803 Phase 2 Brodalumab
39 A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa Terminated NCT01838499 Phase 2
40 A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy of YAZ Compared With Placebo In The Treatment Of Hidradenitis Suppurativa Terminated NCT00722800 Phase 2 drospirenone and ethinyl estradiol (YAZ);Placebo
41 An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa Completed NCT00134134 Phase 1 efalizumab
42 A Multicenter, Open-label, 2-regimen, Repeat-dose Study to Assess the Safety and Pharmacokinetics of Intravenous CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis Not yet recruiting NCT03972280 Phase 1
43 A Phase I, Randomized, Open-label, Parallel-group Study to Determine the Pharmacokinetics, Safety, and Tolerability of MSB11022 (Proposed Adalimumab Biosimilar) Following a Single Subcutaneous Injection by an Auto-injector or by a Pre-filled Syringe in Healthy Subjects Not yet recruiting NCT04018599 Phase 1 40 mg MSB11022;40 mg MSB11022
44 A Comparative Retrospective Study Between Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact Unknown status NCT02999698
45 Group Psychotherapy for Patients With Hidradenitis Suppurativa: Effects in Quality Unknown status NCT02904408
46 The Effect of Intense Pulsed Light Assisted Hair Removal Therapy on Mild and Moderate Cases of Hidrosadenitis Suppurativa Unknown status NCT03203122
47 A Prospective, Randomized, Controlled Clinical Trial Comparing the Efficacy Carbon Dioxide (CO2) Laser Excision Versus Surgical Deroofing in the Treatment of Hidradenitis Suppurativa Unknown status NCT02163746
48 Randomized Control Trial Comparing Efficacy of Antibiotic Therapy Alone Versus Antibiotic Therapy in Conjunction With Quadruple Pulse Therapy Using NdYag Laser in Treatment of Hidradenitis Suppurativa Unknown status NCT01063270 Clindamycin & Rifampin
49 A Prospective Multi-Center Blinded, Randomized, Controlled Clinical Trial Comparing the Efficacy of Provodine Topical Body Wash Versus 10% Benzoyl Peroxide Topical Body Wash for the Treatment of Hidradenitis Suppurativa Unknown status NCT01818167 10% Benzoyl Peroxide Topical Body Wash;Provodine Topical Cream
50 Efficacy of Percutaneous Injection of Triamcinolone in the Treatment of Mammillary Fistula Unknown status NCT01315080

Search NIH Clinical Center for Hidradenitis

Cochrane evidence based reviews: hidradenitis

Sources

Genetic Tests for Hidradenitis

About this section
Sources

Anatomical Context for Hidradenitis

About this section

MalaCards organs/tissues related to Hidradenitis:

41
Neutrophil, Skin, Breast, Myeloid, Thyroid, T Cells, Liver
Sources

Publications for Hidradenitis

About this section

Articles related to Hidradenitis:

(show top 50) (show all 2474)
# Title Authors PMID Year
1
Improving health literacy and treatment understanding of hidradenitis suppurativa using group educational interventions. 38
30582391 2019
2
[Idiopathic granulomatous mastitis associated with erythema nodosum]. 38
31151772 2019
3
Should Patients with Hidradenitis Suppurativa Undergo LASIK? 38
31313219 2019
4
Hemoglobin as an indicator of disease activity in severe hidradenitis suppurativa. 38
30094834 2019
5
Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. 38
31095972 2019
6
Cutaneous plasmacytosis and multinucleate cell angiohistiocytoma-like lesion in a patient with hepatitis B: A fortuitous triad? 38
31070801 2019
7
[Appllication of human acellular dermal matrix in surgical treatment of genitourinary disease]. 38
31420640 2019
8
Metabolic syndrome and inflammatory skin conditions. 38
31169544 2019
9
Anal fistula and pilonidal sinus disease coexisting simultaneously: An audit in a cohort of 1284 patients. 38
31412425 2019
10
IL-38: A New Player in Inflammatory Autoimmune Disorders. 38
31387327 2019
11
Ex vivo human models of hidradenitis suppurativa/acne inversa for laboratory research and drug screening. 38
31321767 2019
12
Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa/ acne inversa. 38
31140657 2019
13
Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data. 38
31073704 2019
14
Targeting the gut-skin axis - probiotics as new tools for skin disorder management? 38
31386766 2019
15
Identifying anemia in a cohort of patients with hidradenitis suppurativa. 38
31374127 2019
16
Factors associated with readmission and mortality in adult patients with skin and soft tissue infections. 38
30770547 2019
17
Remission of severe hidradenitis suppurativa following chemotherapy for Hodgkin's lymphoma. 38
31396947 2019
18
Risk Factors of Sexual Dysfunction in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study. 38
31434072 2019
19
Crystallized phenol for sacral hidradenitis suppurativa. 38
31259621 2019
20
An Association between Hidradenitis Suppurativa and HIV. 38
31407315 2019
21
Complementary and alternative medicine use in hidradenitis suppurativa. 38
31396946 2019
22
Severity staging of hidradenitis suppurativa: is Hurley classification the answer? 38
31281960 2019
23
Inter- and intrarater reliability of Hurley staging for hidradenitis suppurativa. 38
30585304 2019
24
Specimen Collection for Translational Studies in Hidradenitis Suppurativa. 38
31434914 2019
25
Biosimilars in dermatology: The wind of change. 38
31384323 2019
26
Assessing the efficacy of new biologic therapies in hidradenitis suppurativa: consistency vs. bias in outcome measures in moderate and severe disease. 38
30875132 2019
27
The Safety and Impact of a Model of Intermittent, Time-Restricted Circadian Fasting ("Ramadan Fasting") on Hidradenitis Suppurativa: Insights from a Multicenter, Observational, Cross-Over, Pilot, Exploratory Study. 38
31374976 2019
28
The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study. 38
30657173 2019
29
A novel NCSTN missense mutation in the signal peptide domain causes hidradenitis suppurativa, which has features characteristic of an autoinflammatory keratinization disease. 38
31421058 2019
30
Association between hidradenitis suppurativa and hospitalization for psychiatric disorders: a cross-sectional analysis of the National Inpatient Sample. 38
30422314 2019
31
Identification of bacterial DNA in the peripheral blood of patients with active hidradenitis suppurativa. 38
31422449 2019
32
Hidradenitis suppurativa: Current understanding, diagnostic and surgical challenges, and developments in ultrasound application. 38
31423654 2019
33
Into the (gluteal) fold: pilonidal disease and hidradenitis suppurativa - association or continuum? 38
31386167 2019
34
Altered NOX expression does not seem to account for epidermal NLRP3 inflammasome activation in hidradenitis suppurativa. 38
30657189 2019
35
Reply to comment: guselkumab in the treatment of severe hidradenitis suppurativa. 38
30875137 2019
36
Increased risk of cardiovascular comorbidities in hidradenitis suppurativa: A nationwide, population-based, cohort study in Taiwan. 38
31389066 2019
37
Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series. 38
31389375 2019
38
Guselkumab in the Treatment of Concomitant Hidradenitis Suppurativa, Psoriasis, and Crohn's Disease. 38
31389737 2019
39
Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: A multicentre retrospective clinical study. 38
31402725 2019
40
Staphylococcus aureus and host interaction in the flare-ups of hidradenitis suppurativa. 38
31403170 2019
41
The pain of hidradenitis suppurativa: 'We only see what we know'. 38
31403175 2019
42
Pharmacy costs of systemic medications for hidradenitis suppurativa in the United States. 38
30256691 2019
43
The first report of Pseudomonas oryzihabitansin infection in a patient with hidradenitis suppurativa. 38
31428378 2019
44
Neutrophilic eccrine hidradenitis in a healthy Brazilian child. 38
31305012 2019
45
Korean gender differences in hidradenitis suppuratva: nature or nurture? 38
30767281 2019
46
Comparative Overall Comorbidity Burden Among Patients With Hidradenitis Suppurativa. 38
30994865 2019
47
Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa. 38
31288233 2019
48
Thalidomide in Severe Hidradenitis Suppurativa: A Therapeutic Option. 38
31314122 2019
49
How reliable are scoring systems for hidradenitis suppurativa? 38
31353442 2019
50
Koebner phenomenon of hidradenitis suppurativa on a surgical scar. 38
31353763 2019
Sources

Variations for Hidradenitis

About this section
Sources

Expression for Hidradenitis

About this section
Search GEO for disease gene expression data for Hidradenitis.
Sources

Pathways for Hidradenitis

About this section

Pathways related to Hidradenitis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Developmental Biology 66
Show member pathways
 13.08 TNF PSENEN NCSTN KRT14 KRT10 DSG2
2
Th17 cell differentiation 37
Show member pathways
 12.32 TNF NOD2 IL17A IL12RB1
3
Keratinization 66
Show member pathways
 12.21 KRT14 KRT10 DSG2 DSC2
4
Wnt / Hedgehog / Notch 4
11.99 PSENEN PSEN1 NCSTN
5
Tuberculosis 37
11.98 TNF NOD2 CAMP
6
Development NOTCH1-mediated pathway for NF-KB activity modulation 22
Show member pathways
 11.94 PSENEN PSEN1 NCSTN
7
Presenilin-Mediated Signaling 64
11.84 PSENEN PSEN1 NCSTN
8
Th1 Differentiation Pathway 65
Show member pathways
 11.78 TNF IL17A IL12RB1
9
Innate Lymphoid Cell Differentiation Pathways 65
11.51 TNF IL17A IL12RB1
10
p75(NTR)-mediated signaling 1
Show member pathways
 11.4 PSENEN PSEN1 NCSTN
11
A-beta Signaling Pathways 65
11.17 PSENEN PSEN1 NCSTN
12
Development and heterogeneity of the ILC family 1
11.07 TNF IL17A
13
Presenilin action in Notch and Wnt signaling 1
10.99 PSENEN PSEN1 NCSTN
14
Canonical NF-kappaB pathway 1
10.89 TNF NOD2
15
A-beta Pathways: Plaque Formation and APP Metabolism 65
10.49 PSENEN PSEN1 NCSTN
16
Notch Pathway 71
10.07 PSENEN PSEN1
17
Syndecan-3-mediated signaling events 1
10.03 PSENEN PSEN1 NCSTN
Sources

GO Terms for Hidradenitis

About this section

Cellular components related to Hidradenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.56 TNF PSEN1 NOD2 DSG2
2 desmosome GO:0030057 9.16 DSG2 DSC2
3 cornified envelope GO:0001533 9.13 KRT10 DSG2 DSC2
4 gamma-secretase complex GO:0070765 8.8 PSENEN PSEN1 NCSTN

Biological processes related to Hidradenitis according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.79 TNF NOD2 CAMP
2 defense response GO:0006952 9.77 TNF NOD2 CAMP
3 Notch signaling pathway GO:0007219 9.76 PSENEN PSEN1 NCSTN
4 keratinization GO:0031424 9.73 KRT14 KRT10 DSG2 DSC2
5 cornification GO:0070268 9.71 KRT14 KRT10 DSG2 DSC2
6 positive regulation of catalytic activity GO:0043085 9.7 PSENEN PSEN1 NCSTN
7 positive regulation of MAP kinase activity GO:0043406 9.65 TNF PSEN1 NOD2
8 regulation of heart rate by cardiac conduction GO:0086091 9.63 DSG2 DSC2
9 protein processing GO:0016485 9.63 PSENEN PSEN1 NCSTN
10 regulation of synaptic transmission, glutamatergic GO:0051966 9.62 TNF PSEN1
11 positive regulation of interleukin-8 production GO:0032757 9.62 TNF NOD2
12 positive regulation of osteoclast differentiation GO:0045672 9.61 TNF IL17A
13 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.59 NOD2 IL17A
14 negative regulation of growth of symbiont in host GO:0044130 9.58 TNF CAMP
15 amyloid-beta metabolic process GO:0050435 9.57 PSEN1 NCSTN
16 epithelial cell proliferation GO:0050673 9.56 PSEN1 NCSTN
17 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.55 DSG2 DSC2
18 astrocyte activation GO:0048143 9.54 TNF PSEN1
19 membrane protein ectodomain proteolysis GO:0006509 9.54 PSENEN PSEN1 NCSTN
20 cellular response to peptidoglycan GO:0071224 9.51 NOD2 CAMP
21 amyloid precursor protein metabolic process GO:0042982 9.5 PSENEN PSEN1 NCSTN
22 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.49 DSG2 DSC2
23 Notch receptor processing GO:0007220 9.43 PSENEN PSEN1 NCSTN
24 amyloid precursor protein catabolic process GO:0042987 9.33 PSENEN PSEN1 NCSTN
25 Notch receptor processing, ligand-dependent GO:0035333 9.13 PSENEN PSEN1 NCSTN
26 amyloid-beta formation GO:0034205 8.8 PSENEN PSEN1 NCSTN

Molecular functions related to Hidradenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 8.62 DSG2 DSC2
Sources

Sources for Hidradenitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....